CLINICAL TRIALS PROFILE FOR PAROXETINE
✉ Email this page to a colleague
All Clinical Trials for PAROXETINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000368 ↗ | Treatment of Panic Disorder: Long Term Strategies | Completed | National Institute of Mental Health (NIMH) | Phase 3 | 1999-02-01 | Cognitive behavior therapy (CBT) with or without medication has been used in the treatment of panic disorder (PD). The purpose of this study is 1) to determine whether nine months of maintenance cognitive-behavior therapy (CBT) significantly improves the likelihood of sustained improvement; and 2) to determine the acute acceptability and efficacy of medication therapy or continued CBT alone among patients who fail to respond sufficiently to an initial course of CBT alone. It has been found that patients with PD respond as well to CBT or medication alone as they do to a combination of the two. Since the combined treatments are expensive and CBT is associated with less risk of medical toxicity compared to medications, CBT alone will be used first. All patients will first receive CBT alone. If the patient responds to this therapy, the patient will be assigned randomly (like tossing a coin) to 1 of 2 groups. One group will continue to receive CBT (maintenance therapy) for 9 months. The other group of responders will not receive any further therapy. If a patient does not respond to CBT alone, he/she will be assigned randomly to 1 of 2 different groups. One group will receive paroxetine; the other will continue to receive CBT for a longer period. The response to treatment will be evaluated to see which regimen works best to treat PD. The study will last approximately 3 years. An individual may be eligible for this study if he/she has panic disorder with no more than mild agoraphobia (fear of being in public places) and is at least 18 years old. |
| NCT00000368 ↗ | Treatment of Panic Disorder: Long Term Strategies | Completed | New York State Psychiatric Institute | Phase 3 | 1999-02-01 | Cognitive behavior therapy (CBT) with or without medication has been used in the treatment of panic disorder (PD). The purpose of this study is 1) to determine whether nine months of maintenance cognitive-behavior therapy (CBT) significantly improves the likelihood of sustained improvement; and 2) to determine the acute acceptability and efficacy of medication therapy or continued CBT alone among patients who fail to respond sufficiently to an initial course of CBT alone. It has been found that patients with PD respond as well to CBT or medication alone as they do to a combination of the two. Since the combined treatments are expensive and CBT is associated with less risk of medical toxicity compared to medications, CBT alone will be used first. All patients will first receive CBT alone. If the patient responds to this therapy, the patient will be assigned randomly (like tossing a coin) to 1 of 2 groups. One group will continue to receive CBT (maintenance therapy) for 9 months. The other group of responders will not receive any further therapy. If a patient does not respond to CBT alone, he/she will be assigned randomly to 1 of 2 different groups. One group will receive paroxetine; the other will continue to receive CBT for a longer period. The response to treatment will be evaluated to see which regimen works best to treat PD. The study will last approximately 3 years. An individual may be eligible for this study if he/she has panic disorder with no more than mild agoraphobia (fear of being in public places) and is at least 18 years old. |
| NCT00012558 ↗ | Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) | Completed | National Institute of Mental Health (NIMH) | N/A | 1998-09-01 | A long-term study of current treatments for bipolar disorder, including medications and psychosocial therapies. |
| NCT00018733 ↗ | Biological Aspects of Depression and Antidepressant Drugs | Completed | US Department of Veterans Affairs | N/A | 1996-09-01 | This study will be measuring changes in depressive symptoms over a 7 week time period. Double-blind placebo controlled trial using the pharmacologic agents Paroxetine or Desipramine. |
| NCT00018733 ↗ | Biological Aspects of Depression and Antidepressant Drugs | Completed | VA Office of Research and Development | N/A | 1996-09-01 | This study will be measuring changes in depressive symptoms over a 7 week time period. Double-blind placebo controlled trial using the pharmacologic agents Paroxetine or Desipramine. |
| NCT00018759 ↗ | Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients | Completed | SmithKline Beecham | Phase 4 | 2001-03-01 | This study aims to determine if treatment with an SSRI antidepressant medication, paroxetine, is associated with cellular calcium response to serotonin, platelet serotonin receptors, and improvement in mood in depressed patients with or without hypertension. It is hypothesized that platelets of hypertensive patients with depressive symptomatology with be hyper-responsive to serotonin. Additionally, treatment with an SSRI antidepressant is expected to produce a down-regulation of the serotonin receptor with an associated reduction in platelet cytosolic calcium response as well as improved mood. |
| NCT00018759 ↗ | Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients | Completed | US Department of Veterans Affairs | Phase 4 | 2001-03-01 | This study aims to determine if treatment with an SSRI antidepressant medication, paroxetine, is associated with cellular calcium response to serotonin, platelet serotonin receptors, and improvement in mood in depressed patients with or without hypertension. It is hypothesized that platelets of hypertensive patients with depressive symptomatology with be hyper-responsive to serotonin. Additionally, treatment with an SSRI antidepressant is expected to produce a down-regulation of the serotonin receptor with an associated reduction in platelet cytosolic calcium response as well as improved mood. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PAROXETINE
Condition Name
Clinical Trial Locations for PAROXETINE
Trials by Country
Clinical Trial Progress for PAROXETINE
Clinical Trial Phase
Clinical Trial Sponsors for PAROXETINE
Sponsor Name
